The Utility and Interpretation of Ambulatory Glucose Profiles

This supplement is sponsored by Primary Care Education Consortium and Primary Care Metabolic Group and is supported by an educational grant from Abbott.
October 1, 2016|Clinician Reviews

Achieving the glycemic target—a key goal of diabetes management—remains elusive despite pharmacological and technological advances in insulin delivery and glucose monitoring

FACULTY

Davida F. Kruger, MSN, APN-BC, BC-ADM

,

Certified Nurse Practitioner

Henry Ford Medical Group

Division of Endocrinology, Diabetes, Bone, and Mineral

Disease

Detroit, Michigan

DISCLOSURES

Davida Kruger discloses that she is on the advisory boards for Abbott; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and sanofi-aventis U.S. LLC; and on the speakers’ bureaus for Animas Corporation, AstraZeneca; Boehringer Ingelheim/Eli Lilly and Company; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and Valeritas, Inc. She owns stock in Dexcom, Inc.

Stephen Brunton, MD, discloses that he is on the advisory boards and speakers’ bureaus for AstraZeneca; Boehringer Ingelheim; Becton, Dickinson and Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Novo Nordisk. He is also on the advisory board for Abbott Diabetes.

Click here to read the supplement.

To receive CME credit, please read the article and on completion, go to www.pcmg-us.org/agpCME to complete the online evaluation and receive your certificate of completion.